#USA #New York #Levi & Korsinsky #Securities Fraud #Option Care Health

Option Care Health Facing Securities Fraud Investigation

Recent Decline in Stock Performance
Investors in Option Care Health (NASDAQ: OPCH) have recently faced a dramatic downturn as the company's shares plummeted by 25% to 30%. This steep decline followed the announcement of disappointing Q1 2026 revenues that failed to meet Wall Street’s expectations. Furthermore, the company revised its full-year guidance significantly downward, raising concerns among shareholders and prompting an investigation into potential securities fraud.

Financial Overview
On April 30, 2026, Option Care Health reported revenues that fell below analyst projections, leading to a downgrade in its full-year revenue forecast. The original guidance anticipated revenues between $5.8 billion to $6.0 billion. However, this was revised down to a new range of $5.675 billion to $5.775 billion, equating to a cut of approximately $225 million from the previous outlook. The names of CEO John Rademacher and CFO Meenal Sethna echoed optimism just 65 days prior during the Q4 2025 earnings call, making this revision particularly alarming.

Factors Behind the Revenue Shortfall
The company attributed its financial struggles to increased challenges surrounding the conversion of patients to the Stelara biosimilar. Previously cited as a headwind affecting revenues by an estimated $25 million to $35 million for FY 2026, this figure ballooned to $55 million by the end of April 2026, highlighting a substantial shift in patient conversion expectations. A drop in both patient census numbers and revenue projections raised red flags regarding the company's overall market strategies.

Impact on Shareholders
As Option Care Health grapples with these financial hurdles, investors who purchased shares during a period of inflated valuations may be eligible for potential recovery outcomes through legal avenues. Experts from the law firm Levi & Korsinsky are currently calling on affected investors to assess their legal rights, noting that participation in the investigation is free of charge.

Call to Action for Investors
Investors who suffered financial losses due to the steep decline in Option Care Health's stock are encouraged to compile relevant brokerage records such as the dates of purchase, the number of shares bought, and the prices paid. Contact with Levi & Korsinsky can help in gauging potential eligibility for recovery based on these documented losses. It's essential to understand that even if prior shareholders have since sold their stocks, they may still qualify to join the investigation.

Previous Legal Precedents
Levi & Korsinsky has extensive experience in handling securities investigations involving revenue misrepresentations and similar corporate conduct, providing reassurance to concerned shareholders. They are well-equipped to help investors navigate the potential recovery of losses stemming from this downturn.

Conclusion
The securities fraud investigation surrounding Option Care Health's steep stock decline serves as a reminder of the volatile nature of investments in the healthcare industry. As shareholders look for answers, it’s crucial for affected individuals to act swiftly by consulting legal professionals to secure their interests. The situation continues to unfold, and more details are expected as the investigation proceeds.